← Oncology Approval Tracker

FDA DECISION ·

Balversa

erdafitinib · Janssen Biotech

Traditional approvalTraditional conversionUrothelial carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic urothelial carcinoma with an FDA test-confirmed susceptible FGFR3 alteration and progression after at least one systemic treatment line. It is not recommended for patients eligible for, but not previously treated with, a PD-1 or PD-L1 inhibitor.

LAMPGEN ANALYSIS

Why it matters

The traditional approval revised the earlier accelerated indication, including a shift from FGFR2 or FGFR3 to qualifying FGFR3 alterations.

What research teams should watch

Check the actual FGFR report and checkpoint therapy history, and schedule phosphate and ophthalmic monitoring.

PRIMARY RECORDS

Sources